Can-Fite Biopharma To Pursue Global Licensing And Strategic Partnerships Using Its Phase IIa Pancreatic Cancer Results
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its participation in
Can-Fite showed some promise in early pancreatic cancer tests. Now they're looking for partners to help develop the drug further.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.